 |
|||||||||||||||||||
|
|||||||||||||||||||
 |
| Metabolic syndrome | |||
The metabolic syndrome refers to a group of metabolic alterations including obesity, hyperglucemia and hypertension which affect a large number of the population of developed countries. Different approaches can be used to control it, and in our group, in particular we deal with anti-obesity agents, mainly PPAR alpha agonists and cannabinoid antagonists, either as single entities or as multiple ligands, and also with PPAR alpha agonists for the treatment of hyperglucemia. |
|||
|
|||
References:
- Decara, J. M.; Romero-Cuevas, M.; Rivera, P.; Macías González, M.; Vida, M.; Pavón, F. J.; Serrano, A.; Cano, C.; Fresno, N.; Pérez-Fernández, R.; Rodríguez de Fonseca, F.; Suarez, J.
“Elaidyl-sulfamide, a oleylethanolamide-modeled antiobesity drug, reduces body weight gain and plasma colesterol in rats” Dis. Model. Mech. 2012, 5, 660-670.
- Alonso, M.; Serrano, A.; Vida, M.; Crespillo, A.; Hernandez-Folgado, L.; Jagerovic, N.; Goya, P.; Reyes-Cabello, C.; Perez-Valero, V.; Decara, J.; Macias-Gonzales, M.; Bermudez Silva, F.J.; Suarez, J.; Rodriguez de Fonseca, F. Pavon, F.J.
“Anti-obesity efficacy of LH-21, a cannabinoid CB1 receptor antagonist with poor brain penetration, in diet-induced obese rats” Br. J. Pharmacol. 2012, 165(7), 2274-2291.
- Cano, C.; Paez, J.A.; Goya, P.; Serrano, A.; Pavon, J.; Rodriguez de Fonseca, F.; Suardiaz, M.; Martin, M.I.
“Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide” Eur. J. Med. Chem. (2009), 44(12), 4889-4895.
- Alvarado, M., Goya, P., Macías-González, M., Pavón F. J., Serrano, A., Jagerovic, N., Elguero, J., Gutierrez-Rodríguez, A., García-Granda, S., Suardaz, M., Rodríguez de Fonseca, F.
"Antiobesity designed multiple ligands: synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents".
- Pavón, F.J., Serrano, A., Pérez-Valero, V., Jagerovic, N., Hernández-Folgado, L., Macías, M., Goya, P., Rodríguez de Fonseca, F. J.
"Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effect of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in zucker rats"
- Cano, C., Pavón, F. J., Serrano, A.; Goya, P., Páez. J. A., Rodríguez de Fonseca, F., Macias, M.
"Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPAR alpha activation" J. Med. Chem. 2007, 50, 389-393.
Patents:
• Bermúdez F. J., Rodríguez de Fonseca F., Romero M., Jagerovic N., Fernández Fernández C., Goya P.
"Derivados de pirazol bivalentes como inhibidores de ingesta" Application number: ES P200930120; WO2010128191 (Titular entity: Fundación IMABIS/CSIC)
• Rodríguez de Fonseca F., Macías González M., Serrano A., Goya P., Alvarado M., Elguero J., Jagerovic N. "Pyrazole derivatives of fatty acid amides as PPAR-alpha receptor specific activators, preparation method and use of same" Application number: ES200702691; WOES000653; WO2009050318 (Titular entity: Fundación IMABIS/CSIC)
• Cano C., Pavón F. J., Serrano A., Goya P., Páez J. A., Rodríguez de Fonseca F., Macias M.
"Acyclic sulfamide derivatives"Â Application number: ES20060000184, WO2007EP00681, ES2288107, WO20071085469 (Titular entity: Fundación IMABIS/CSIC licensed to Pharmamar)
|
